GPA33-pretargeted radioimmunotherapy with mono- and bivalent DOTA-based Lu-177-labeled radiohaptens in a mouse orthotopic liver xenograft model of metastatic human colorectal cancer., PMID:40521192
Radioimmunotherapy for peritoneal carcinomatosis: Preclinical proof of concept to clinical translation., PMID:40154493
Identification and validation of a novel autoantibody biomarker panel for differential diagnosis of pancreatic ductal adenocarcinoma., PMID:39949781
Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent 177Lu-Labeled Radiohapten., PMID:39168519
Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment., PMID:37509078
Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis., PMID:34667111
An integrated magneto-electrochemical device for the rapid profiling of tumour extracellular vesicles from blood plasma., PMID:34183802
GPA33 is expressed on multiple human blood cell types and distinguishes CD4+ central memory T cells with and without effector function., PMID:33728639
Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses., PMID:33052220
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting., PMID:32865839
Selective Photokilling of Colorectal Tumors by Near-Infrared Photoimmunotherapy with a GPA33-Targeted Single-Chain Antibody Variable Fragment Conjugate., PMID:32396000
A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis., PMID:31928310
An N-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy., PMID:31891487
Dual Radionuclide Theranostic Pretargeting., PMID:31483993
Toward the Optimization of Click-Mediated Pretargeted Radioimmunotherapy., PMID:30912951
Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma., PMID:30429889
Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers., PMID:30082472
A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer., PMID:29935333
Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer., PMID:29866746
Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer., PMID:28705917
Heterogeneous expression of A33 in colorectal cancer: possible explanation for A33 antibody treatment failure., PMID:27272411
Mapping the Aggregation Kinetics of a Therapeutic Antibody Fragment., PMID:26692229
Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates., PMID:26596724
CF750-A33scFv-Fc-Based Optical Imaging of Subcutaneous and Orthotopic Xenografts of GPA33-Positive Colorectal Cancer in Mice., PMID:26090413
Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin α-sarcin in nude mice bearing human colorectal cancer xenografts., PMID:25883890
Preparation of an engineered safer immunotoxin against colon carcinoma based on the ribotoxin hirsutellin A., PMID:25752204
Monoclonal antibody-functionalized multilayered particles: targeting cancer cells in the presence of protein coronas., PMID:25712076
Quantitative intratumoural microdistribution and kinetics of (131)I-huA33 antibody in patients with colorectal carcinoma., PMID:24995151
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer., PMID:24691674
68Ga chelating bioorthogonal tetrazine polymers for the multistep labeling of cancer biomarkers., PMID:24589653
Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer., PMID:23294608
Targeting cancer cells: controlling the binding and internalization of antibody-functionalized capsules., PMID:22872125
Production and characterization of scFvA33T1, an immunoRNase targeting colon cancer cells., PMID:22748038
Production and characterization of a colon cancer-specific immunotoxin based on the fungal ribotoxin α-sarcin., PMID:22718791
124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET., PMID:22068895
(124)I-huA33 antibody PET of colorectal cancer., PMID:21764796
Immuno-PET of cancer: a revival of antibody imaging., PMID:21764784
Gold hybrid nanoparticles for targeted phototherapy and cancer imaging., PMID:20154383
High-level expression of a phage display-derived scFv in Pichia pastoris., PMID:19554300
KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines., PMID:19551868
Clearance kinetics and external dosimetry of 131I-labeled murine and humanized monoclonal antibody A33 in patients with colon cancer: radiation safety implications., PMID:19359848
Biodistribution and efficacy of [131I]A33scFv::CDy, a recombinant antibody-enzyme protein for colon cancer., PMID:18360720
A33 antigen displays persistent surface expression., PMID:18236042
Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer., PMID:17786329
Influence of size, surface, cell line, and kinetic properties on the specific binding of A33 antigen-targeted multilayered particles and capsules to colorectal cancer cells., PMID:19206525
In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer., PMID:17127172
A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma., PMID:17034367
Glycoprotein A34, a novel target for antibody-based cancer immunotherapy., PMID:16405301
In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma., PMID:16248767
For research use only. Not for human or drug use.
